Antidepressant discontinuation during pregnancy and risk of mental health-related emergencies

Psychiatry
Depression and anxiety are common mental health conditions that may persist or recur during pregnancy, often requiring ongoing pharmacological treatment to maintain maternal well-being. Antidepressants are widely used to manage these disorders, with continued treatment often necessary to prevent symptom relapse. However, concerns about fetal exposure, medication safety, and potential pregnancy outcomes may lead some women to discontinue antidepressants after conception. Discontinuation of effective treatment may increase the risk of psychiatric symptom recurrence, clinical deterioration, and the need for urgent mental health intervention. Therefore, understanding the association between antidepressant discontinuation during pregnancy and mental health-related emergencies is important for optimising perinatal mental healthcare and supporting individualised treatment decisions.[1]Patterns and consequences of antidepressant discontinuationTreatment interruption: Patients taking selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) before conception may stop treatment during pregnancy because of concerns about fetal safety or advice to avoid medication exposureTiming of discontinuation: Treatment interruption frequently occurs during the first trimester, although discontinuation may also occur later in pregnancy. This can leave patients vulnerable to symptom recurrence during different stages of the perinatal periodRisk of symptom recurrence: Discontinuation may lead to the return or worsening of depressive and anxiety symptoms, particularly in patients with recurrent illness, previous severe episodes, or incomplete remissionWithdrawal symptoms: Abrupt discontinuation of SSRIs and SNRIs may cause dizziness, nausea, fatigue, sleep disturbances, agitation, and anxiety. These symptoms can complicate the assessment of an underlying psychiatric conditionAssociation with mental health-related emergenciesIncreased emergency care: Recent clinical evidence has associated antidepressant discontinuation during pregnancy with higher rates of behavioral health-related emergency department visits compared with treatment continuationPersistence after delivery: The increased use of emergency mental health services may extend into the postpartum period, when hormonal changes, sleep disruption, and new caregiving demands can further affect psychological well-beingImportance of treatment continuity: A separate population-based analysis also identified an association between discontinuation during pregnancy and increased psychiatric emergency risk, supporting the importance of maintaining appropriate treatmentInterpretation of evidence: These findings demonstrate an association rather than a proven causal relationship. Differences in underlying illness severity, treatment history, and reasons for discontinuation may influence the observed outcomesClinical management and risk reductionClinicians should review psychiatric history, previous treatment response, illness severity, and relapse risk before making decisions about antidepressant use during pregnancyEffective pharmacological treatment should not be withheld or discontinued solely because a patient is pregnantPatients considering discontinuation should receive individualized counseling about potential maternal and fetal risks, benefits, and available treatment optionsWhen discontinuation is clinically appropriate, gradual dose reduction under medical supervision should be considered to minimize withdrawal symptomsRegular assessment of mood, anxiety, sleep, functioning, and treatment adherence should continue throughout pregnancy and postpartumPatients with worsening symptoms or a history of severe psychiatric illness may require coordinated care involving obstetric and mental health specialistsClinical warning signs requiring prompt assessmentClinical findingRecommended clinical responsePersistent worsening of depressive symptomsReassess symptom severity and current treatmentSevere anxiety or panic symptomsEvaluate functional impairment and need for additional supportMarked sleep disturbanceAssess mood symptoms, anxiety, and contributing factorsSuicidal thoughts or self-harm riskArrange immediate safety assessment and urgent psychiatric evaluationPsychotic symptoms or severe behavioral changesInitiate emergency psychiatric assessmentConclusionAffective disorders are common during pregnancy and may require continued pharmacological treatment to maintain maternal mental health and prevent relapse. Antidepressant discontinuation during pregnancy may increase the risk of psychiatric symptom recurrence, clinical deterioration, and mental health-related emergencies, particularly among women with pre-existing depression or anxiety. Therefore, treatment decisions should carefully balance potential medication-related risks against the consequences of untreated or recurrent psychiatric illness. Individualised counselling, continuity of effective treatment, gradual dose reduction when clinically appropriate, and regular antenatal and postpartum monitoring are essential to support maternal mental well-being and minimise preventable psychiatric emergencies.[2]Reference(s):1. Liu X, Molenaar N, Agerbo E, et al. Antidepressant discontinuation before or during pregnancy and risk of psychiatric emergency in Denmark: A population-based propensity score-matched cohort study. PLoS Med. 2022;19(1):e1003895. Published 2022 Jan 31. doi:10.1371/journal.pmed.1003895. https://pmc.ncbi.nlm.nih.gov/articles/PMC8843130/2. Trinh NTH, Munk-Olsen T, Wray NR, et al. Timing of Antidepressant Discontinuation During Pregnancy and Postpartum Psychiatric Outcomes in Denmark and Norway. JAMA Psychiatry. 2023;80(5):441-450. doi:10.1001/jamapsychiatry.2023.0041. https://pmc.ncbi.nlm.nih.gov/articles/PMC9996461/